Steve, I understand your frustration, but suggest a broader frame of reference. If you'll read back in this thread, 4,000 messages ago, you'll see that Agouron reported whenever there was data. They didn't pump the stock by mentioning the number of HIV+ people in the world along with how excited they were to be entering Phase _X_ trials, which would be complete in only _Y_ weeks.
As a result, a number of us developed confidence that what Agouron said was true, and we invested in a sound story, supported by data and not fanned by press releases. It is not possible to overstate the importance of clinical data, presented in peer-reviewed journals and at reputable scientific conferences. Anyone can write a press release, but only solid data withstands challenge by scientists.
Accordingly, a number of us took large positions in what was regarded as a Don Quixote stock, tilting at Merck. I used the profit from my Agouron investment for a down payment on an excellent home in the country (I didn't even have to sell the one in town). If they were a constant-press-release company, I never would have invested that much money.
Patience! Be glad that you can count on what they say. |
